JUNIPER: a Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
All subjects were treated with ND‐L02‐s0201 or placebo for 24 weeks (a total of 12 doses). Subject's participation in the study was approximately 40 weeks including a Screening and Baseline period of up to 6 weeks, a treatment period of 24 weeks (including the 2 weeks after the last study treatment), and a follow‐up period of 10 weeks after End‐of‐Treatment (EOT).
Epistemonikos ID: 17996355e5bc45dace2acc204aa9103c266bb7ca
First added on: May 21, 2024